trial

Study Evaluating HTC-867 in Healthy Young and Elderly Subjects

NCTId NCT00827489
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 72 (estimated)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2009-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
72 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2009-01
Primary completion
2009-04
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
HTC-867

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
72
Phase
PHASE1
Primary Completion Date
2009-04
Status
TERMINATED
relationships
The graph out of here
drug
HTC-867
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Healthy Subjects
indication